Show simple item record

FieldValueLanguage
dc.contributor.authorHarbeck, Nadia
dc.contributor.authorPenault-Llorca, Frédérique
dc.contributor.authorCortes, Javier
dc.contributor.authorGnant, Michael
dc.contributor.authorHoussami, Nehmat
dc.contributor.authorPoortmans, Philip
dc.contributor.authorRuddy, Kathryn
dc.contributor.authorTsang, Janice
dc.contributor.authorCardoso, Fatima
dc.date.accessioned2023-03-07T03:03:02Z
dc.date.available2023-03-07T03:03:02Z
dc.date.issued2019en_AU
dc.identifier.urihttps://hdl.handle.net/2123/30163
dc.description.abstractBreast cancer is the most frequent malignancy in women worldwide and is curable in ~70–80% of patients with early-stage, non-metastatic disease. Advanced breast cancer with distant organ metastases is considered incurable with currently available therapies. On the molecular level, breast cancer is a heterogeneous disease; molecular features include activation of human epidermal growth factor receptor 2 (HER2, encoded by ERBB2), activation of hormone receptors (oestrogen receptor and progesterone receptor) and/or BRCA mutations. Treatment strategies differ according to molecular subtype. Management of breast cancer is multidisciplinary; it includes locoregional (surgery and radiation therapy) and systemic therapy approaches. Systemic therapies include endocrine therapy for hormone receptor-positive disease, chemotherapy, anti-HER2 therapy for HER2-positive disease, bone stabilizing agents, poly(ADP-ribose) polymerase inhibitors for BRCA mutation carriers and, quite recently, immunotherapy. Future therapeutic concepts in breast cancer aim at individualization of therapy as well as at treatment de-escalation and escalation based on tumour biology and early therapy response. Next to further treatment innovations, equal worldwide access to therapeutic advances remains the global challenge in breast cancer care for the future.en_AU
dc.language.isoenen_AU
dc.publisherNature reviewsen_AU
dc.relation.ispartofNature Reviews Disease Primersen_AU
dc.rightsCreative Commons Attribution 4.0en_AU
dc.subjectbreast canceren_AU
dc.subjectepidemiologyen_AU
dc.subjectmalignancyen_AU
dc.titleBreast Canceren_AU
dc.typeArticleen_AU
dc.identifier.doi10.1038/s41572-019-0111-2
dc.type.pubtypePublisher's versionen_AU
dc.relation.otherNational Breast Cancer Foundation (NBCF, Australia) Breast Cancer Research Leadership Fellowship
dc.relation.otherNational Centre for Advancing Translational Sciences: KL2 TR002379
usyd.facultySeS faculties schools::Faculty of Medicine and Health::Sydney School of Public Healthen_AU
usyd.citation.volume5en_AU
usyd.citation.issue1en_AU
usyd.citation.spage66en_AU
workflow.metadata.onlyYesen_AU


Show simple item record

Associated file/s

There are no files associated with this item.

Associated collections

Show simple item record

There are no previous versions of the item available.